Immune checkpoint inhibitors in elderly patients with lung cancer: evidence from phase 3 trials.

Current opinion in oncology(2023)

引用 0|浏览1
暂无评分
摘要
In this article, we summarize the results from recent phase III clinical trials that have evaluated the use of ICIs as first-line or second-line monotherapy, in combination with chemotherapy and other immunotherapies in elderly patients with lung cancer.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要